Moderna, Inc. (MRNA) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Moderna, Inc. (MRNA): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 26/100 — a percentile rank of Moderna, Inc.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.
| Market cap | $76.9B |
| P / S | 34.5× |
| EV / EBITDA | -24.6× |
| Gross margin | 23.4% |
| Operating margin | -149.0% |
| Net margin | -141.4% |
| Return on equity | -46.6% |
| ROIC | -60.1% |
| Revenue growth | -27.6% |
| Debt / equity | 0.1× |
| Dividend yield | 0.0% |
Is Moderna, Inc. overvalued? P/S looks overvalued vs its 5-year range; P/B looks overvalued vs its 5-year range.
Independent of the events above — derived from Moderna, Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact